With the public-private partnership between the CAMH and the US company Assurex Health, AssureRx Canada has been established to provide patients with a personalized approach to match the right medication at the right dose based on their genetic makeup.
Using Assurex Health’s proprietary GeneSight pharmacogenomic technology, physicians can determine which psychiatric medications are likely to be more effective for each patient and which ones are not likely to be effective, often avoiding treatment failure and side effects. The CAMH/AssureRx Canada collaboration will enable research discoveries from CAMH to be brought into widespread clinical use utilizing Assurex Health’s expertise in developing, validating, and bringing new psychiatric pharmacogenomics tests into routine clinical application.
A key initial priority of the CAMH/AssureRx partnership includes GeneSight testing of 20,000 Ontario patients, though the CAMH IMPACT study, for the purpose of improving patient treatment outcomes, promoting personalized medicine, and reducing mental health care costs across the Province of Ontario. AssureRx Canada plans to launch its first Canadian GeneSight Psychotropic test panel covering antidepressants and antipsychotics later this summer, making it available to all Canadians in 2014.
Get in Touch
250 College Street
1 (800) 928-3316